Pharmaceutical industry leaders Novartis, Amgen, and Bristol-Myers Squibb—among others—released third-quarter 2013 results showing increased sales.
Novartis reported group net sales up 4%, or 6% on a constant-currency basis, over the third-quarter of 2012 to $14.3 billion in the third quarter of 2013, the company said in a press release. The company’s underlying business, excluding the impact of patent expiries, demonstrated strong growth, with underlying net sales up 10% on a constant-currency basis in the third quarter. Although all divisions contributed to growth, the company’s growth products were particularly strong with 17% growth in the quarter. Novartis’ sales in emerging markets showed 9% growth on a constant-currency basis for the quarter, led by China and Russia.
Amgen reported 11% product sales growth in the third-quarter of 2013, the company said in a press release. Total revenues for the third quarter were $4.7 billion. In the third quarter, Amgen closed on its acquisition of Onyx Pharmaceuticals and began operation of the Amgen–Astellas alliance in Japan and the Betta Pharma joint venture in China.
Bristol-Myers Squibb’s net sales were up 9% to $4.1 billion in the third quarter, the company announced in a press release. Leading products with double-digit growth included Yervoy (ipilimumab), Onglyza(saxagliptin)/Kombiglyze (saxagliptin and metformin hydrochloride), Sprycel (dasatinib), and Orencia (abatacept).